1. M19 Differences in patient and physician viewpoints of the management of idiopathic pulmonary fibrosis (ipf). (15th November 2017) Authors: Maher, TM; Swigris, JJ; Kreuter, M; Wijsenbeek, M; Axmann, J; Ireland, L; Nathan, SD Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. M30 Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials. (15th November 2017) Authors: Maher, TM; Inoue, Y; Case, AH; Sakamoto, W; Stowasser, S; Wuyts, WA Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P10 Weight loss is a feature of progressive disease in idiopathic pulmonary fibrosis. (12th November 2019) Authors: Barth, S; Hogben, C; King, M; Vitri, B; Mann, J; George, P; Kokosi, M; Kouranos, V; Renzoni, E; Wells, AU; Chua, F; Maher, TM; Molyneaux, PL Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P113 Secreted Lysyl Oxidase is Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis. (19th November 2012) Authors: Calderwood, CJ; Jones, MG; Hoile, L; Havelock, T; Maher, TM; O'Reilly, KMA; Davies, DE Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P157 Hiatus hernia is highly prevalent in idiopathic pulmonary fibrosis and impacts disease progression. (December 2018) Authors: Desai, SR; Mackintosh, JA; Chua, F; Renzoni, E; Kouranos, V; Margaritopoulos, G; Kokosi, M; Maher, TM; Wells, AU; Molyneaux, PL; Kumar, S; George, PM Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P161 Unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF) – insights from patient chart review in five european countries. (15th November 2016) Authors: Maher, TM; Molina-Molina, M; Russell, A-M; Bonella, F; Jouneau, S; Ripamonti, E; Axmann, J; Vancheri, C Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P164 Cyclophosphamide for the treatment of refractory chronic hypersensitivity pneumonitis. (December 2018) Authors: Hastings, RA; Saunders, P; Hogben, C; Mackintosh, JA; Patel, S; Chua, F; Renzoni, EA; Kokosi, M; Kouranos, V; Wells, AU; George, PM; Maher, TM; Molyneaux, PL Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P201 Rituximab as rescue therapy in interstitial lung disease refractory to conventional immunosuppression. (14th November 2013) Authors: Abdullah, RR; Ming, D; Keir, GJ; Maher, TM; Wells, AU; Renzoni, EA Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P23 Target And Biomarker Discovery For Hedgehog Pathway Activity In Idiopathic Pulmonary Fibrosis In Support Of A Phase 2 Randomised, Double-blind, Placebo-controlled Study To Assess Efficacy And Safety Of Vismodegib In Ipf (island). (10th November 2014) Authors: Jia, G; Chandriani, S; Abbas, AR; DePianto, D; N'Diaye, E; Yaylaoglu, M; Collard, HR; Wolters, P; Egen, J; Scalori, A; Ackrill, A; Hou, J; Kaminski, J; Maher, TM; Arron, JR Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P248 Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of fvc percent predicted. (15th November 2016) Authors: Ward, K; Spurr, L; Goldman, NR; Margaritopoulos, GA; Kokosi, M; Renzoni, E; Chua, F; Maher, TM; Ward, S; Wells, AU Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗